Lexaria Bioscience Corp.
LEXX
$0.62
$0.000.36%
NASDAQ
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.05% | 52.04% | 49.85% | 29.95% | 77.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.05% | 52.04% | 49.85% | 29.95% | 77.65% |
| Cost of Revenue | -100.00% | -43.75% | -43.75% | -84.57% | -86.83% |
| Gross Profit | 5.63% | 53.04% | 50.96% | 35.12% | 90.59% |
| SG&A Expenses | 1.36% | 7.25% | 52.60% | 79.14% | 49.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.92% | 99.00% | 141.75% | 76.40% | 26.84% |
| Operating Income | -44.42% | -102.79% | -150.04% | -80.00% | -24.42% |
| Income Before Tax | -47.34% | -105.06% | -134.05% | -71.74% | -19.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.37% | -105.06% | -134.05% | -71.74% | -19.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -12.38% | -27.82% | -52.83% | -63.84% | -73.75% |
| Net Income | -47.45% | -105.37% | -134.87% | -72.50% | -20.23% |
| EBIT | -44.42% | -102.79% | -150.04% | -80.00% | -24.42% |
| EBITDA | -45.05% | -103.97% | -155.55% | -83.67% | -26.26% |
| EPS Basic | -17.16% | -44.43% | -40.50% | 17.83% | 43.62% |
| Normalized Basic EPS | -15.06% | -44.00% | -53.18% | 13.55% | 41.18% |
| EPS Diluted | -17.16% | -44.43% | -40.50% | 17.83% | 43.62% |
| Normalized Diluted EPS | -15.06% | -44.00% | -53.18% | 13.55% | 41.18% |
| Average Basic Shares Outstanding | 34.67% | 45.91% | 63.21% | 85.50% | 92.88% |
| Average Diluted Shares Outstanding | 34.67% | 45.91% | 63.21% | 85.50% | 92.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |